JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB267174

Human ZCCHC2 knockout A549 cell line

Be the first to review this product! Submit a review

|

(0 Publication)

ZCCHC2 KO cell line available to order. KO validated by. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 1. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.

View Alternative Names

9930114B20Rik, AW212015, DKFZp451A185, FLJ20281, KIAA1744, MGC112793, MGC13269, TNFRSF11A, ZCHC2_HUMAN, Zinc finger CCHC domain-containing protein 2

1 Images
Sanger Sequencing - Human ZCCHC2 knockout A549 cell line (AB267174)
  • Sanger seq

Unknown

Sanger Sequencing - Human ZCCHC2 knockout A549 cell line (AB267174)

Homozygous : 1 bp insertion in exon1

Key facts

Cell type

A549

Species or organism

Human

Tissue

Lung

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 1

Disease

Carcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab267174-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255450 Human wild-type A549 cell line", "number":"AB267174-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab267174 Human ZCCHC2 knockout A549 cell line", "number":"AB267174-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab267174-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab267174 Human ZCCHC2 knockout A549 cell line", "number":"AB267174-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab267174-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab267174 Human ZCCHC2 knockout A549 cell line", "number":"AB267174-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
ZCCHC2
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
  • Do not allow the cell density to exceed 7x104 cells/cm2.
Culture medium

F-12K + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The zinc finger CCHC domain-containing protein 2 also known as ZCCHC2 functions mechanically as an RNA-binding protein. It plays a role in RNA metabolic processes. ZCCHC2 is approximately 90 kDa in mass and includes several zinc finger motifs that are important for its interaction with RNA. It is expressed highly in the nucleus of cells across various tissues with notable levels in the brain and other central nervous system structures. This indicates its involvement in regulating RNA under specific physiological conditions.
Biological function summary

ZCCHC2 interacts with the cellular machinery involved in RNA splicing and processing. It is part of ribonucleoprotein complexes that facilitate these functions. This protein assists in modulating RNA stability and contributes to the precise processing required for mature RNA molecules. These activities are important for maintaining proper gene expression by ensuring that RNA transcripts are accurately produced and modified before translation occurs.

Pathways

ZCCHC2 plays a role in RNA processing and degradation pathways. It acts within the spliceosomal complex aiding in the proper removal of introns from pre-mRNA. ZCCHC2 interacts with other proteins such as components of the Human spliceosome which include splicing factors that orchestrate the splicing process. It also connects with pathways linked to RNA surveillance mechanisms where it helps in quality control of RNA transcripts.

ZCCHC2 has connections to neurological conditions and cancer. Abnormal expression levels or mutations in ZCCHC2 may relate to altered splicing activities leading to neurodevelopmental disorders. Additionally its dysregulation might contribute to the genesis of certain cancers through disrupted RNA processing. Proteins like spliceosomal components and RNA-binding proteins are usually involved in such diseases highlighting the importance of balanced ZCCHC2 function for cellular health.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Male

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com